Corning Awarded Additional Patent for Label-free Drug Development Technology
Removing biomolecular labels and purification steps improves data quality and biological relevance of assay results
The study of molecular interactions in high-throughput screening has become an essential part of the drug discovery process. Many conventional screening methods require highly purified molecules as well as complex labeling methods, both of which can compromise the biological relevance of the interactions being studied.
Applications such as hybridoma screening and cell lysates require the ability to detect biomolecular interactions in complex samples. "The ability of the Corning Epic System to screen complex samples such as cell lysates and supernatants in drug discovery represents a significant step forward in rapidly identifying novel and biologically relevant interactions," said Mannix Aklian, commercial development manager and the Corning inventor responsible for this new patent.
This latest patent, U.S. Patent No. 7,349,080 entitled "Label-independent Detection of Unpurified Analytes," adds to Corning's patent portfolio related to the Epic System and label-free, optical biosensor technology. Previously, Corning acquired exclusive rights to U.S. Patent No. 5,738,825, a fundamental patent related to optical-based biosensors in a microplate format.
Other news from the department research and development
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.